Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2016
Editora
BIOMED CENTRAL LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BMC CARDIOVASCULAR DISORDERS, v.16, article ID 2, 6p, 2016
Resumo
Background: Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation drugs has been questioned. Our goal is to evaluate the effects of smoking cessation drugs on blood pressure and heart rate in patients from a smoking cessation service in a cardiology hospital. Methods: We examined the PAF database (Smoking Cessation Assistance Program database) between January 2008 and March 2014. We analyzed data from 900 patients who were compliant with the treatment (50.5 % male, average age 53 +/- 17 years). The most frequent clinical diagnoses were coronary artery disease (25.2 %), hypertension (57.2 %), and diabetes (13.4 %). Blood pressure, heart rate, and carbon monoxide (CO) concentration in exhaled air were analyzed at consecutive visits during the first 45 days of treatment (mean visits - 3). Analysis of repeated measures was used for the statistical analysis (p < 0.05). Results: Two hundred seventy one patients used nicotine replacement therapy (NRT) alone, 81 used bupropion alone, 154 used varenicline alone, 283 used NRT plus bupropion and 111 used bupropion plus varenicline. For all smoking cessation drugs, used alone or in combination, no increase occurred in the average value of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Significant reductions in CO concentrations occurred in all smoking cessation drug groups. Conclusion: Smoking cessation drugs used in monotherapy or in combined regimens did not influence systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in this group of patients during the observation period.
Palavras-chave
Smoking cessation, Nicotine replacement therapy, Bupropion, Varenicline, Cardiovascular disease, Hypertension
Referências
- DACOSTA A, 1993, EUR HEART J, V14, P1709
- Issa JS, 2011, TOB CONTROL, V20, P156, DOI 10.1136/tc.2010.037614
- Tanus-Santos JE, 2001, AM J HYPERTENS, V14, P610, DOI 10.1016/S0895-7061(01)01301-2
- Issa JS, 2013, NICOTINE TOB RES, V15, P1146, DOI 10.1093/ntr/nts230
- Sobieraj DM, 2013, J AM SOC HYPERTENS, V7, P61, DOI 10.1016/j.jash.2012.11.003
- FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549
- Najem B, 2006, HYPERTENSION, V47, P1162, DOI 10.1161/01.HYP.0000219284.47970.34
- ROOSE SP, 1991, AM J PSYCHIAT, V148, P512
- Tonstad S, 2003, EUR HEART J, V24, P946, DOI 10.1016/S0195-668X(03)00003-4
- Settle EC, 1999, CLIN THER, V21, P454, DOI 10.1016/S0149-2918(00)88301-0
- Mills EJ, 2014, CIRCULATION, V129, P28, DOI 10.1161/CIRCULATIONAHA.113.003961
- Thase ME, 2008, J CLIN PSYCHOPHARM, V28, P302, DOI 10.1097/JCP.0b013e318172424e
- Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128
- Glantz S, 2012, LANCET, V379, P1269, DOI 10.1016/S0140-6736(11)60615-6
- Eisenberg MJ, 2013, J AM COLL CARDIOL, V61, P524, DOI 10.1016/j.jacc.2012.08.1030
- Issa JS, 2012, J BRAS PNEUMOL, V38, P761, DOI 10.1590/S1806-37132012000600012
- Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64
- Zevin S, 1998, CLIN PHARMACOL THER, V64, P87, DOI 10.1016/S0009-9236(98)90026-1
- Singh S, 2011, CAN MED ASSOC J, V183, P1359, DOI 10.1503/cmaj.110218
- Rigotti NA, 2010, CIRCULATION, V121, P221, DOI 10.1161/CIRCULATIONAHA.109.869008
- Rigotti NA, 2006, AM J MED, V119, P1080, DOI 10.1016/j.amjmed.2006.04.024
- Ebbert JO, 2014, JAMA-J AM MED ASSOC, V311, P155, DOI 10.1001/jama.2013.283185
- Fiore MC, 2008, TREATING TOBACCO USE
- Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8
- Prochaska JJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2856
- Roose S P, 2000, Am Heart J, V140, P84, DOI 10.1067/mhj.2000.109977
- Rose JE, 2014, AM J PSYCHIAT, V171, P1199, DOI 10.1176/appi.ajp.2014.13050595
- Yugar-Toledo Juan Carlos, 2005, J Clin Hypertens (Greenwich), V7, P721, DOI 10.1111/j.1524-6175.2005.04597.x